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Abstract
OBJECTIVE: Imatinib is a small-molecule tyrosine kinase inhibitor capable of selective, dual inhibition
of the transforming growth factor beta and platelet-derived growth factor (PDGF) pathways. Imatinib
has previously been shown to prevent the development of inflammation-driven experimental fibrosis
when treatment was initiated before administration of the profibrotic stimulus. The aim of this study was
to confirm the efficacy of imatinib in a murine model of systemic sclerosis (SSc) that is less driven by
inflammation and to investigate whether imatinib is also effective for the treatment of established
fibrosis. METHODS: The tight skin 1 (TSK-1) mouse model of SSc was used to evaluate the
antifibrotic effects of imatinib in a genetic model of the later stages of SSc. In addition, the efficacy of
imatinib for the treatment of preestablished fibrosis was analyzed in a modified model of
bleomycin-induced dermal fibrosis in which the application of bleomycin was prolonged and the onset
of treatment was late. RESULTS: Treatment with imatinib reduced dermal and hypodermal thickening
in TSK-1 mice and prevented the differentiation of resting fibroblasts into myofibroblasts. In the model
of preestablished dermal fibrosis, imatinib not only stopped further progression of fibrosis but also
induced regression of preexisting dermal fibrosis, with a reduction in dermal thickness below
pretreatment levels. CONCLUSION: These results indicate that combined inhibition of the tyrosine
kinase c-Abl and PDGF receptor might be effective in the later, less inflammatory stages of SSc and for
the treatment of established fibrosis. Thus, imatinib might be an interesting candidate for clinical trials
in patients with longstanding disease and preexisting tissue fibrosis.
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